Skip to main content

View full-text article in PMC

. 2006 Nov 28;4:7. doi: 10.1186/1476-8518-4-7

Table 1.

Study Population Characteristics

Patient No.	MHC Class I			Before HAART Intensification		Before First Treatment Interruption (TI)
	A	B	C	CD4 Cell Count (cells/mm³)	CD4 Cell %	CD4 Cell Count (cells/mm³)	CD4 Cell %

14001	A2/A26	B18/B39	Cw7/Cw12	990	30	1120	33
14002	A2/A1	B60/B51	Cw3/Cw14	330	25	280	25
14003	A1/A3	B7/B8	Cw7/-	650	25	590	27
14004	A2/A3	B38/B44	Cw5/Cw12	400	19	370	22
14005	A3/A69	B35/B44	Cw12/Cw7	230	21	510	27
14006	A1/-	B8/B57	Cw6/Cw7	440	23	410	24
14007	A36/A68	B7/B53	Cw4/Cw7	370	16	320	17
14008	A1/A68	B8/B60	Cw3/Cw7	350	14	720	19
14009	A3/A29	B35/B44	Cw4/Cw16	710	37	800	38
14010	A2/A66	B7/B14	Cw7/Cw8	290	24	370	37
Median (range)				476 (230–990)	23.4 (16–37)	549 (280–1120)	25.9 (17–38)